Minerva Surgical to Announce Second Quarter 2022 Financial Results

Rhea-AI Summary

Minerva Surgical, Inc. (Nasdaq: UTRS) announced its upcoming release of the second quarter 2022 financial results on August 9, 2022. A conference call and webcast will occur at 1:30 PM PT to discuss these results and recent developments. The company is focused on treating Abnormal Uterine Bleeding (AUB) with minimally invasive solutions aimed at preserving the uterus and avoiding unnecessary hysterectomies. This event is part of their ongoing commitment to women's health and aims to provide insights into their financial performance and product innovations.

Positive

• Focus on developing minimally invasive solutions for women's health.
• Broad product line addressing Abnormal Uterine Bleeding (AUB) needs.
• Upcoming financial results announcement may indicate growth or positive metrics.

Negative

• None.

SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

About Minerva Surgical, Inc.

Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

MEDIA CONTACT

Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676

INVESTOR RELATIONS CONTACT

Caroline Corner
investors@minervasurgical.com
415-202-5678

RELATED LINKS

https://www.aubandme.com

https://www.minervasurgical.com 

FAQ

When will Minerva Surgical release its second quarter 2022 financial results?

Minerva Surgical will release its second quarter 2022 financial results on August 9, 2022.

What time is the conference call for Minerva Surgical's financial results?

The conference call will take place at 1:30 PM Pacific Time on August 9, 2022.

How can I access the Minerva Surgical conference call?

Participants can register for the call through the company's website to receive dial-in information.

What is the focus of Minerva Surgical, Inc.?

Minerva Surgical focuses on providing minimally invasive solutions for treating Abnormal Uterine Bleeding in women.

What is the stock symbol for Minerva Surgical?

Minerva Surgical is traded under the stock symbol UTRS.